Dopa-decarboxylase inhibitor + dopamine precursor. ≥18yrs: Do not crush or chew. Patients not receiving levodopa: initially one Sinemet CR 50–200 tab twice daily, at intervals of at least 6 hrs.

Medically reviewed by Nicholas R. Metrus, MD Key Takeaways Facial masking is a common symptom seen in people with Parkinson's ...

Avion Pharmaceuticals, an Alora Pharmaceuticals subsidiary company focused on advancing treatment for Parkinson's disease, is proud to announce the findings from a recently published study examining ...

The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...

The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...

Parkinsons disease, a progressive movement disorder, weakens, damages, and destroys brain cells that control movement. Treatments for Parkinsons stimulate or mimic dopamine (a brain messenger), which ...

One effective strategy for using Parkinson’s drugs is to start with a dopamine agonist. Explain to patients that this is the background dosing they will take on a regular schedule. Begin with a ...

VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV ...

Report in the Journal of Parkinson's Disease presents data from one-year trial on long-term safety, efficacy, and quality of life in advanced PD patients using levodopa-carbidopa intestinal gel ...